Antibody characterisation – an essential researchers’ resource
Central to reproducibility in biomedical research is the ability to use well-characterised and defined reagents. The CPTAC Antibody Portal serves as a National Cancer Institute community resource that provides access to many standardised renewable affinity reagents to cancer-associated targets and accompanying characterisation data. Nikki Withers spoke to Dr Tara Hiltke who oversees the NCI’s Antibody Characterization Program to hear how researchers can benefit from this valuable resource.
ANTIBODIES are among the most commonly used tools in the biological sciences and are utilised in numerous experiments to identify and isolate other molecules. However, many cancer researchers lack access to affordable, well-characterised and analytically validated renewable affinity reagents, a problem that could be hindering cancer biomarker discovery and validation, cancer diagnostics development and therapeutics monitoring.1 In an effort to accelerate cancer research and provide well-characterised monoclonal antibodies to the scientific community, the National Cancer Institute’s (NCI’s) Office of Cancer Clinical Proteomics Research launched the Antibody Characterization Program as part of the Clinical Proteomic Technologies for Cancer (CPTC) initiative. “This is a community resource for scientists based on what they need,” explained Program Director, Dr Tara Hiltke. “Our reagents are produced, screened and selected for specific applications, so it is possible for us to work with researchers to create antibodies that could potentially be used for therapeutic applications.”
Biocompare, Clinical Proteomic Technologies for Cancer (CPTC), Developmental Studies Hybridoma Bank (DSHB), Frederick National Laboratory for Cancer Research, National Cancer Institute (NCI), National Institutes of Health, NCI Antibody Characterisation Laboratory (ACL), NCI Office of Cancer Clinical Proteomics Research
Dr Tara Hiltke (National Cancer Institute)